XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
XTL BIOPHARMACEUTICALS LTD.
Industry:
Biotechnology Developer Platform Pharmaceutical
Founded:
1993-01-01
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.xtlbio.com
Total Employee:
1+
Status:
Active
Contact:
+972 9-955-7080
Email Addresses:
[email protected]
Total Funding:
2.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt WordPress Apache Wordpress Plugins Mobile Non Scaleable Content Microsoft Exchange Online PHP
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Employees Featured
Stock Details
Official Site Inspections
http://www.xtlbio.com Semrush global rank: 5.94 M Semrush visits lastest month: 1.39 K
- Host name: 172.67.189.193
- IP address: 172.67.189.193
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "XTL Biopharmaceuticals Ltd."
About Us - XTLbio
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the …See details»
Directors | XTLbio
Shlomo Shalev serves as a director in our company since December 2014, and starting September 2015 serves as the company's Chairman. most recently served as Chairman of the Board of Micronet, a TASE listed company. In …See details»
XTL Names Mr. Noam Band as its New Chief Executive Officer
Apr 7, 2025 Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd....See details»
XTL Biopharmaceuticals Ltd. - Crunchbase Company Profile
Sub-Organization of . Yeda Research and Development Co. Ltd . Founded Date 1993; Operating Status ... Company Type For Profit; Contact Email [email protected]; Phone Number +972 9 …See details»
XTL Biopharmaceuticals Company Description - Stock Analysis
2 days ago Company profile for XTL Biopharmaceuticals Ltd. (TLV:XTLB) with a description, list of executives, contact details and other key facts.See details»
XTL Biopharmaceuticals Ltd. | Company Profile - OTC Markets
Www.xtlbio.com. 972 3 611 6666. [email protected]. Business Description. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the development, in-licensing, acquisition, …See details»
Executive Management | XTLbio
Shlomo Shalev joined our Board of Directors in December 2014 and was appointed Chief Executive Officer in May, 2020.Most recently served as Chairman of the Board of Micronet, a TASE listed company. In addition to …See details»
XTL Biopharmaceuticals - Products, Competitors, Financials, …
XTL Names Mr. Noam Band as its New Chief Executive Officer. Apr 7, 2025. April 07, 2025 09:15 ET Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April …See details»
XTL Biopharmaceuticals Ltd. - LinkedIn
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of …See details»
XTL Biopharmaceuticals Company Profile | Management and
[email protected]: 6: first_last: [email protected]: 7: last: [email protected]: Your Questions, Our Answers Get Free Access to XTL Biopharmaceuticals Contacts Info. What is …See details»
XTL Names Mr. Noam Band as its New Chief Executive Officer
Apr 7, 2025 XTL holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the …See details»
XTL Biopharmaceuticals - Craft
Oct 29, 2024 See insights on XTL Biopharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
XTL Biopharmaceuticals (XTLB) Company Profile & Description
Apr 15, 2025 Company profile for XTL Biopharmaceuticals Ltd. (XTLB) stock, with a description, list of executives, contact details and other key facts.See details»
XTL Biopharmaceuticals Ltd. - Cruelty Free Investing
Our Opinion. XTL Biopharmaceuticals is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in pre-clinical stage trials of their pharmaceuticals.See details»
Corporate Governance | XTLbio
Election of Directors and Terms of Office Our Board of Directors currently consists of seven members, including our non-executive Chairman. Other than our two external directors, our …See details»
XTL Biopharmaceuticals Confirms that it has not Experienced any ...
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical …See details»
XTL Biopharmaceuticals Confirms that it has not Experienced any ...
Oct 20, 2023 XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following indices: Tel-Aviv …See details»
XTL Biopharmaceuticals Confirms that it has not Experienced
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) (See details»
Investors - XTLbio
Established in 1993, XTL became a public company in 2000. XTL's ADRs (1:20 ratio) are publicly traded on the NASDAQ and its shares are traded on the Tel Aviv Stock Exchange (NASDAQ: …See details»
Orphan Therapeutics Accelerator Announces Foundational …
1 day ago BOSTON, April 23, 2025--The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and commercializing therapies for …See details»